Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03457129 · ClinicalTrials.gov registry record · Phase 4
Fycompa Titration Intervals and Effects on Retention Rate
A Phase 4 study of Epilepsy, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03457129: Completed Phase 4 study of Epilepsy, sponsored by University of Arizona.
NCT03457129 is a Phase 4 study of Epilepsy that has completed, run by University of Arizona. The registered enrollment target is 20 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03457129, a Phase 4 study of Epilepsy, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will aim to improve retention and tolerability by slowing the initial titration rate of perampanel from a standard up-titration rate of 2 week intervals to a slower up-titration rate consisting of 3 week intervals. Subjects will be randomized to either perampanel, standard titration interval rate (Group A) or perampanel, slower titration interval rate (Group B).
Primary Outcome
Retention rate, which indirectly measures the therapeutic tolerance, will be measured at 52 weeks in each group.
Conditions Studied
Interventions
- DRUG Perampanel Oral Tablet
Study Locations (1)
Arizona
- Banner University Medical Center Phoenix - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2021-12-15 |
| Phase | Phase 4 |
What the finished NCT03457129 record still lists
NCT03457129 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Perampanel Oral Tablet is the first listed.
NCT03457129 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT03457129 about?
NCT03457129 is a clinical study titled "Fycompa Titration Intervals and Effects on Retention Rate". This study will aim to improve retention and tolerability by slowing the initial titration rate of perampanel from a standard up-titration rate of 2 week intervals to a slower up-titration rate consisting of 3 week intervals. Subjects will be randomized to either perampanel, standard titration inter...
What is the current status of trial NCT03457129?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2018-04-18. Estimated completion is 2021-12-15.
What conditions does trial NCT03457129 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT03457129?
The interventions under investigation include: Perampanel Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03457129?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03457129 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03457129's enrollment target sits among peer trials
20 131st of 160 higher than 24 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care
RECRUITING · Phase 4
-
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
RECRUITING · Phase 4
-
Epidiolex® for Anxiety in Pediatric Epilepsy
COMPLETED · Phase 4
-
Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia
COMPLETED · Phase 4
-
Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy
COMPLETED · Phase 4
-
Levetiracetam for Benign Rolandic Epilepsy
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI